Dr. Reddy’s Laboratories shares in focus after acquiring India trademarks for two HRT drugs for $32 million

robot
Abstract generation in progress

Dr. Reddy’s Laboratories has acquired the India trademarks for the Hormone Replacement Therapy (HRT) drugs Progynova® and Cyclo-Progynova® from Mercury Pharma Group Limited for $32.15 million. This strategic acquisition is expected to significantly bolster Dr. Reddy’s gynecology portfolio and mark its entry into the HRT segment in India, drawing investor attention to its shares. Despite a slight dip in share price on Wednesday, the company shows strong technical indicators and a shift in institutional holdings with mutual funds increasing their stake while FPIs reduced theirs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)